Detalhe da pesquisa
1.
What are the patients' and health care professionals' understanding and behaviors towards adverse drug reaction reporting and additional monitoring?
Pharmacoepidemiol Drug Saf
; 30(3): 334-341, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33099846
2.
Is patient exposure preapproval and postapproval a determinant of the timing and frequency of occurrence of safety issues?
Pharmacoepidemiol Drug Saf
; 27(2): 168-173, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29278866
3.
Literature review of visual representation of the results of benefit-risk assessments of medicinal products.
Pharmacoepidemiol Drug Saf
; 25(3): 238-50, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26521865
4.
Balancing benefit and risk of medicines: a systematic review and classification of available methodologies.
Pharmacoepidemiol Drug Saf
; 23(7): 667-78, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24821575
5.
COVID-19 Vaccines and Heavy Menstrual Bleeding: The Impact of Media Attention on Reporting to EudraVigilance.
Drug Saf
; 2024 Apr 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38607521
6.
The Role of the European Medicines Agency in the Safety Monitoring of COVID-19 Vaccines and Future Directions in Enhancing Vaccine Safety Globally.
Drug Saf
; 47(5): 405-418, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38396269
7.
Safety Monitoring of COVID-19 Vaccines: Perspective from the European Medicines Agency.
Clin Pharmacol Ther
; 113(6): 1223-1234, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36524423
8.
Improving the Safety of Medicines in the European Union: From Signals to Action.
Clin Pharmacol Ther
; 107(3): 521-529, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31621897
9.
Promoting and Protecting Public Health: How the European Union Pharmacovigilance System Works.
Drug Saf
; 40(10): 855-869, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28735357
10.
Patient Reporting in the EU: Analysis of EudraVigilance Data.
Drug Saf
; 40(7): 629-645, 2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28417320
11.
A description of signals during the first 18 months of the EMA pharmacovigilance risk assessment committee.
Drug Saf
; 37(12): 1059-66, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25398646